血塞通对兔下肢缺血再灌注自由基信号的影响

目的:探讨血塞通对下肢缺血再灌注损伤的保护作用。方法:采用电子自旋共振技术和电子自旋共振捕集技术(N-tert-butyl-2-phenylnitrone,PBN)观察兔下肢缺血再灌注时出现PBN-自旋加合物信号。结果:该信号强度与缺血时间有关,缺血4h再灌注时的信号明显强于缺血2h再灌注;血塞通对该自旋加合物信号有明显猝熄作用。结论:血塞通对下肢缺血再灌注损伤具有一定的保护作用。     

血塞通注射液体外溶血反应研究

目的:研究血塞通注射液对人血红细胞溶血度的影响,为其临床安全应用提供依据。方法:将血塞通注射液(含三七总皂甙100mg)稀释为25mg/ml,16.7mg/ml,及10mg/ml试液,用分光光度法和常规肉眼观察法测定试液所致人血红细胞溶血度。结果:浓度为25mg/ml及16.7mg/ml的试液引起溶血反应,但10mg/ml试液未致溶血反应。结论:血塞通注射液的溶血反应与其浓度有关。因此,血塞通注射应在使用前稀释至适宜的浓度,浓度<10mg/ml的溶液较为安全。     

Clinical Observation of the Effect of Xuesaitong Soft Capsule (血塞通软胶囊)on Post-hepatitis Fibrosis

Objective:To study the effect of Xuesaitong soft capsule (血塞软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zheter treatment. Results: The levels of serum procollagen Ⅲ, hyaluronic acid, collagen Ⅳ, laminin in the two groups were significantly lower (P＜0.01) than those before treatment. The differences between the two groups were insignificant (P＞0.05). Conclusion: XST could recover liver dysfunction and had anti-liver fibrosis function.     

HPLC测定血塞通肠溶滴丸人参皂苷Rg1、人参皂苷Rb1、三七皂苷R1的含量

目的:研究血塞通肠溶滴丸中人参皂苷Rg1、人参皂苷Rb1、三七皂苷R1的含量测定方法。方法:采用HPLC法测定人参皂苷Rg1、人参皂苷Rg1、三七皂苷R1的含量。结果:人参皂苷Rg1、人参皂苷Rb1、三七皂苷R1三者的平均加样回收率分别为100.35%、102.01%、100.13%;RSD分别为1.34%、1.48%、1.78%,n=6。结论:该方法简便,灵敏,重现性好,可作为血塞通肠溶滴丸中人参皂苷Rg1、人参皂苷Rb1、三七皂苷R1的含量测定方法。     

RP-HPLC梯度法测定血塞通滴丸中三七皂苷R1、人参皂苷Rb1及人参皂苷Rg1的含量

目的 :用高效液相色谱梯度洗脱法同时检测血塞通滴丸中三七皂苷R1、人参皂苷Rb1、人参皂苷Rg13种皂苷含量的方法 ,为制定质量标准中含量测定方法及含量限度提供了依据。方法 :用大连SpherisorbC18分析柱 ,乙腈 水线性梯度洗脱 ,0～ 15min(2 0∶80 - 4 0∶6 0 ) ,流速 1.0mL·min-1,检测波长 2 0 3nm。结果 :R1,Rf1和Rb1线性范围分别为 1.0 2～ 9.18μg ,4 .8～ 4 3.4 μg和 4 .6～ 4 1.6 μg。该方法回收率R1为 10 1.0 % (RSD =3.18% ) ,Rb1为 10 0 .0 % (RSD =1.19% ) ,Rg1为 99.5 % (RSD =3.0 2 % )。结论 :HPLC梯度洗脱法能将多种皂苷很好地分离检测 ,提高了时效 ,减少了误差 ,结果表明该方法准确可靠 ,重现性好 ,结果稳定     

血塞通对大鼠脑缺血再灌注损伤的保护作用

目的观察血塞通预处理对大鼠脑缺血再灌注损伤的保护作用。方法采用线栓法复制大鼠大脑中动脉脑缺血再灌注损伤模型，检测血液流变学指标，并测定再灌注后缺血侧丙二醛（MDA）含量超氧化物歧化酶（SOD）活性。结果血塞通不同程度降低高、中、低切变率全血黏度、红细胞压积和血沉，能拮抗缺血脑组织脑MDA含量的增加，提高脑组织SOD含量。结论血塞通对大鼠大脑中动脉缺血再灌注损伤具有明显保护作用。     

血塞通注射液联合甲钴胺治疗糖尿病周围神经病变的临床观察

目的 观察血塞通注射液联合甲钴胺注射液治疗糖尿病周围神经病变（DPN）的临床疗效。方法将40例DPN在控制血糖的基础上随机分为两组，治疗组采用血塞通注射液联合甲钴胺注射液治疗，对照组只采用甲钴胺注射液。疗程均为4周，观察两组治疗前后的变化。结果经治疗后两组的自觉症状、体征以及神经传导速度均有改善，但治疗组明显优于对照组，两组间差异有显著性（P〈0．01）。结论 血塞通注射液联合甲钴胺注射液可明显改善糖尿病周围神经病变，疗效肯定，值得，临床推广应用。     

Chinese preparation Xuesaitong promotes the mobilization of bone marrow mesenchymal stem cells in rats with cerebral infarction

After cerebral ischemia, bone marrow mesenchymal stem cells are mobilized and travel from the bone marrow through peripheral circulation to the focal point of ischemia to initiate tissue regeneration. However, the number of bone marrow mesenchymal stem cells mobilized into peripheral circulation is not enough to exert therapeutic effects, and the method by which blood circulation is promoted to remove blood stasis influences stem cell homing. The main ingredient of Xuesaitong capsules is Panax notoginseng saponins, and Xuesaitong is one of the main drugs used for promoting blood circulation and removing blood stasis. We established rat models of cerebral infarction by occlusion of the middle cerebral artery and then intragastrically administered Xuesaitong capsules(20, 40 and 60 mg/kg per day) for 28 successive days. Enzyme-linked immunosorbent assay showed that in rats with cerebral infarction, middle- and high-dose Xuesaitong significantly increased the level of stem cell factors and the number of CD117-positive cells in plasma and bone marrow and significantly decreased the number of CD54-and CD106-positive cells in plasma and bone marrow. The effect of low-dose Xuesaitong on these factors was not obvious. These findings demonstrate that middle- and high-dose Xuesaitong and hence Panax notoginseng saponins promote and increase the level and mobilization of bone marrow mesenchymal stem cells in peripheral blood.     

血塞通注射液治疗冠心病心绞痛的临床分析

目的观察血塞通注射液治疗冠心病心绞痛的临床疗效。方法将72例冠心病心绞痛的住院患者随机分为两组,治疗组36例用血塞通注射液,对照组36例用丹参注射液,15d为1疗程。观察两组治疗前后临床症状及心电图改善。结果治疗组患者的心绞痛总有效率为91.67%,心电图改善总有效率为80.56%,治疗组的显效率及总有效率均高于对照组,且差异有统计学意义(P<0.05)。结论血塞通注射液治疗冠心病心绞痛疗效满意,值得推广应用。     

血塞通注射液指纹图谱研究

目的采用超高效液相色谱-紫外检测器-质谱(UPLC/UV/MS)法对血塞通注射液进行指纹图谱研究,并对其有效成分进行定性。方法采用Waters Acquity UPLCTM BEH C18柱(100 mm×2.1 mm,1.7μm),以乙腈-10 mmol/L醋酸铵溶液进行二元线性梯度洗脱,流速0.2 mL/min。离子化模式为ESI+。结果得到了分离度和重现性均较好的血塞通注射液超高效液相色谱-紫外检测器-质谱指纹图谱,标示了8个共有峰。结论超高效液相色谱-紫外检测器-质谱法可以用于血塞通注射液的快速鉴定及质量控制。